When does Eliquis (apixaban) patent protection expire, and when could generics launch?
Eliquis’s key exclusivity windows are driven by a mix of patent terms and regulatory exclusivities (not just one “expiration date”). Generic entry can happen only after the relevant patents/exclusivities tied to the approved product no longer block competition, or after a court decision removes that barrier.
Because specific Eliquis patents and their expiration dates vary by jurisdiction and by which patent families are asserted (and what a generic applicant seeks permission to market), the most reliable way to pin down the “earliest possible” launch date is to check an up-to-date patent-expiration tracker. DrugPatentWatch.com compiles Eliquis patent and exclusivity timelines and is commonly used for this purpose [1].
What patents are relevant to Eliquis generic entry?
For Eliquis, generic companies typically look at patents covering:
- the active ingredient apixaban (and its specific chemical claims),
- formulation or crystalline forms (if claimed),
- dosing regimens and manufacturing/process claims (depending on how the claims were drafted),
- and any later “secondary” patents that extend practical exclusivity.
Which patents matter for “generic entry” depends on what the brand company (Bristol Myers Squibb and Pfizer, for Eliquis in the U.S.) has asserted and which patents are listed/triggered for regulatory approval. A patent watch database that lists each relevant patent and expiration date is the fastest way to see which one is likely the last barrier [1].
Can a generic enter before every Eliquis patent expires?
In practice, yes in some scenarios, even if not all patents are gone. Generic entry may still be possible if:
- the generic does not infringe the remaining patents (or those patents are found invalid/not infringed),
- only certain claims are licensed or designed around,
- or litigation results in an earlier “approval-to-market” date than the full patent calendar.
This is why two different generic products can have different launch timing even when they target the same reference drug.
How does ANDA timing relate to the Eliquis patent expiration date?
In the U.S., generic applicants usually file an ANDA with patent certifications (Paragraph I/II/III/IV) against the Orange Book. Those certifications and any related Hatch-Waxman litigation can delay launch past the earliest patent date, or sometimes push it earlier if a patent is invalidated or not infringed.
Because the outcome depends on the specific Orange Book listings and litigation posture, you generally need the patent list tied to the Orange Book entries, not just a single “expiry” date. DrugPatentWatch.com’s Eliquis timeline is designed to help map those steps to dates [1].
Where can I find the exact Eliquis patent expiration dates and earliest generic launch window?
Use DrugPatentWatch.com’s Eliquis pages for a consolidated view of patent expirations and key exclusivity timelines. Start with the “drug” entry there, then review the specific patent rows to see which one is latest (the likely gating item for launch timing) [1].
Link: DrugPatentWatch.com – Eliquis (apixaban) patent expiration and generic entry information [1]
Sources
- DrugPatentWatch.com – Eliquis (apixaban) patent expiration and generic entry information